Tempo Scan Pacific Partners with Chinese Pharmaceutical Firm for Biopharmaceutical Venture
PT Tempo Scan Pacific Tbk (TSPC) has partnered with Chinese pharmaceutical company Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to form a joint venture that will focus on developing the biopharmaceutical business in Indonesia.
The plan to establish the joint venture was disclosed by TSPC through an information submission to the Indonesia Stock Exchange on Friday (17/7/2026). The two companies will set up a new entity named PT Tempo CTTQ Biopharmaceutical Indonesia, which is expected to serve as a strategic vehicle for expanding the development and marketing of biotherapeutic products in the domestic market.
This move signals Tempo Scan Pacific’s seriousness in capturing growth opportunities in the biopharmaceutical sector, which is projected to continue rising alongside the growing demand for technology-based healthcare services and biological therapies in Indonesia.
Through this synergy, both companies hope to accelerate technology transfer in modern pharmaceuticals whilst delivering high-quality biotherapeutic products that are more accessible to the Indonesian public.
Tempo Scan Pacific’s management explained that the joint venture formation process is being carried out in accordance with the Financial Services Authority Regulation (POJK) No. 31/POJK.04/2015 on Disclosure of Material Information or Facts by Issuers or Public Companies.
TSPC has yet to disclose the investment value or the shareholding composition of each party in PT Tempo CTTQ Biopharmaceutical Indonesia. This information will be announced once all legal documents related to the joint venture’s establishment have been officially signed.
With the formation of this joint venture, Tempo Scan Pacific is not only broadening its business portfolio but also opening opportunities to accelerate the development of the biopharmaceutical industry in Indonesia through collaboration with a global player possessing experience and state-of-the-art technology.
As of the first quarter of 2026, the company recorded revenues of Rp 3.41 trillion, up 4.12% year-on-year. Meanwhile, TSPC’s net profit fell 14.03% year-on-year to Rp 351.81 billion.
During that period, the pharmaceutical segment contributed Rp 1.1 trillion in revenue, whilst consumer and cosmetic products contributed Rp 1.22 trillion. Distribution services accounted for Rp 1.09 trillion.
TSPC’s share price fell 0.38% to Rp 2,590 per share on Monday (20/7/2026). Over the past five days, however, TSPC shares have risen 3.6%.
Source: jawawa.id (https://jawawa.id/newsitem/tempo-scan-pacific-partners-with-chinese-pharmaceutical-firm-for-biopharmaceutical-venture-1784548213)
Originally published by investasi.kontan.co.id (https://investasi.kontan.co.id/news/tempo-scan-tspc-gandeng-farmasi-china-bidik-bisnis-biopharmaceutical), translated from Indonesian